Last reviewed · How we verify
ginsenoside RE
Ginsenoside RE is a natural triterpenoid saponin from ginseng that modulates multiple cellular pathways including stress response, anti-inflammatory, and antioxidant mechanisms.
Ginsenoside RE is a natural triterpenoid saponin from ginseng that modulates multiple cellular pathways including stress response, anti-inflammatory, and antioxidant mechanisms. Used for Marketed as dietary supplement/traditional medicine for general wellness and stress adaptation.
At a glance
| Generic name | ginsenoside RE |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Natural product/herbal extract |
| Modality | Small molecule |
| Therapeutic area | General wellness/Adaptogenic |
| Phase | FDA-approved |
Mechanism of action
Ginsenoside RE acts as an adaptogen, enhancing cellular stress resistance and promoting homeostasis through activation of heat shock proteins and antioxidant defense systems. It exhibits anti-inflammatory properties by inhibiting pro-inflammatory cytokine production and modulating immune cell function. The compound also demonstrates neuroprotective and cardioprotective effects through multiple signaling pathways including MAPK and PI3K/Akt pathways.
Approved indications
- Marketed as dietary supplement/traditional medicine for general wellness and stress adaptation
Common side effects
- Gastrointestinal upset
- Insomnia
- Headache
Key clinical trials
- The Effect of Farlong® NotoGinseng™ (Ginseng Plus®) on Cholesterol and Blood Pressure (PHASE2)
- Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke (NA)
- A Clinical Trial of Ginseng in Diabetes (EARLY_PHASE1)
- The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction (PHASE4)
- Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study (PHASE4)
- Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ginsenoside RE CI brief — competitive landscape report
- ginsenoside RE updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI